Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Core Viewpoint - Tarsus Pharmaceuticals, Inc. is set to report its third quarter 2025 financial results and provide a corporate update through a live webcast on November 4, 2025 [1] Company Overview - Tarsus Pharmaceuticals, Inc. focuses on revolutionizing treatment for patients, particularly in eye care, by applying proven science and new technology [2] - The company is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including eye care and infectious disease prevention [2] - XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved for treating Demodex blepharitis in the United States [2] - Tarsus is developing TP-04 as an ophthalmic gel for potential treatment of Ocular Rosacea and TP-05 as an oral tablet for potential prevention of Lyme disease, both currently in Phase 2 [2]